company background image
IHL

Incannex Healthcare ASX:IHL Stock Report

Last Price

AU$0.28

Market Cap

AU$333.4m

7D

40.0%

1Y

1.8%

Updated

09 Aug, 2022

Data

Company Financials
IHL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IHL Stock Overview

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia.

Incannex Healthcare Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Incannex Healthcare
Historical stock prices
Current Share PriceAU$0.28
52 Week HighAU$0.76
52 Week LowAU$0.18
Beta2.47
1 Month Change16.67%
3 Month Change-23.29%
1 Year Change1.82%
3 Year Change221.84%
5 Year Change1,300.00%
Change since IPO221.84%

Recent News & Updates

Shareholder Returns

IHLAU PharmaceuticalsAU Market
7D40.0%4.3%0.7%
1Y1.8%-11.5%-8.0%

Return vs Industry: IHL exceeded the Australian Pharmaceuticals industry which returned -11.5% over the past year.

Return vs Market: IHL exceeded the Australian Market which returned -8% over the past year.

Price Volatility

Is IHL's price volatile compared to industry and market?
IHL volatility
IHL Average Weekly Movement16.1%
Pharmaceuticals Industry Average Movement12.2%
Market Average Movement10.5%
10% most volatile stocks in AU Market17.6%
10% least volatile stocks in AU Market4.6%

Stable Share Price: IHL is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: IHL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
20013Joel Lathamhttps://www.incannex.com.au

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company’s products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases.

Incannex Healthcare Limited Fundamentals Summary

How do Incannex Healthcare's earnings and revenue compare to its market cap?
IHL fundamental statistics
Market CapAU$333.41m
Earnings (TTM)-AU$12.80m
Revenue (TTM)AU$720.43k

500.0x

P/S Ratio

-28.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IHL income statement (TTM)
RevenueAU$720.43k
Cost of RevenueAU$548.32k
Gross ProfitAU$172.11k
Other ExpensesAU$12.97m
Earnings-AU$12.80m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.01
Gross Margin23.89%
Net Profit Margin-1,776.19%
Debt/Equity Ratio0.0%

How did IHL perform over the long term?

See historical performance and comparison